Close

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...
- Advertisement -

IBM Watson Health selected iBio to receive 18 months use of the IBM clinical development (ICD) solution at no cost.

IBM Watson Health recently began offering its clinical development solution to eligible trial sponsor organizations as part of its efforts to help support the medical community to address the COVID-19 pandemic. IBM Watson is currently working with 15 COVID-19 disease trials.

“We are deeply appreciative of IBM’s vote-of-confidence, which recognizes the potential of iBio’s COVID-19 vaccine development efforts from among the hundreds of organizations that applied for access to IBM’s ICD solution,” Tom Isett, co-chairman and CEO of iBio, said in a statement.

Mr. Isett said the IBM technology would help accelerate clinical trials of iBio’s COVID-19 vaccine candidates. It also complements iBio’s FastPharming System’s core speed, quality and scale-up advantages in the development of vaccines and therapeutics.

“Through strategic collaborations like this one, we believe iBio is now poised with the tools, technology and capital necessary to compete in the fight against COVID-19,” Mr. Isett added

iBio expects data from the preclinical immunization studies of its two COVID-19 vaccine candidates, IBIO-200 and IBIO-201, which are being conducted at Texas A&M University System laboratories, will be available in the third quarter of 2020.

Mary Presti, VP for life sciences with IBM Watson Health, said IBM is committed to leveraging its ICD solution to help accelerate the timelines for COVID-19 clinical trials and are enabling access to the platform, free of charge, for relevant trial sponsors.

“We are inspired by iBio’s commitment, as well as all of the other leaders in the life sciences community, as they apply their expertise and ingenuity to help millions of patients worldwide,” she added.

ICD is a unified, software-as-a-solution-based electronic data capture platform, designed to provide end-to-end visibility as well as patient, site, and clinical trial management capabilities. ICD is designed to help clinical trial sponsors and clinical site staff reduce the time and cost of clinical trials by centralizing and organizing information, providing 24/7 access to clinical trial data via a single URL from any web-enabled device, and providing a flexible and scalable data management platform to help design and manage clinical trials by incorporating optional clinical trial-specific features and services.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »